Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Tonocard discontinuation

Executive Summary

AstraZeneca will discontinue Tonocard (tocainide) in U.S. Dec. 31. Approved in 1984 to treat severe irregular heartbeat, company says newer products now dominate market. Tonocard was one of original Astra Merck collaborations (1"The Pink Sheet" Nov. 7, 1994, p. 9). Merck currently manufacturers the drug for AstraZeneca. Worldwide sales in 2002 were approximately $1.2 mil., the bulk of which were in the U.S, AstraZeneca says...

You may also be interested in...



ASTRA COUNTING ON LONG-TERM INDICATION FOR PRILOSEC HELP PAY OFF $820 MIL. BUY-IN TO ASTRA MERCK; JOINT VENTURE SALES ARE $860 MIL THROUGH NINE MONTHS

Astra is looking to a long-term indication for Prilosec to help pay off its $820 mil. investment in Astra Merck, Inc.

QUOTED. 21 April 2021. Nicholas McQuaid.

A patient recruiter got 10 years in prison for his role in a scheme to convince seniors to get unneeded and expensive genetic tests. Nicholas McQuaid, acting assistant attorney general of the Justice Department’s Criminal Division, discussed the case.

Is The US FDA At A Tipping Point?

Wall Street is worried that a cluster of recent negative regulatory events means tougher reviews going forward. That concern is probably overdone, but a year into the COVID pandemic is a good time to take stock of how FDA is doing.

UsernamePublicRestriction

Register

PS041916

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel